Modernas Flu vaccines show positive results at the later stages, indicating the possibility of communal combination shots

Modernas Flu vaccines show positive results at the later stages, indicating the possibility of communal combination shots

 Modanya announced that the experimental influenza vaccine reached its primary objectives in late clinical research and marked an important milestone in its efforts to expand beyond the Covid 19 vaccine.  

Moderna reported Monday that mRNA-1010, a mRNA-based influenza-based, exhibited a strong immune response against four tribes of seasonal influenza, responding to standards for both security and efficacy studies. The study has more than 6,000 adults in several countries, showing antibody responses with  comparable or superior results compared to the currently approved influenza vaccine. 

“These positive data enhance the potential of  mRNA platforms beyond Covid-19,” said Moderna Sté Phan Bancel CEO, highlighting the company is currently preparing to submit regulations. If this is approved, this will be the second selling vaccine of modernity after his Covid-19 shot.  

Paving routes for combined vaccines

The success of mRNA-1010 will promote Moderna’s strategic plan and develop a combination vaccine aimed at several respiratory viruses. The company is actively testing formulations combining the flu and Covid 19 vaccine into one annual shot to simplify its vaccination programme and improve its records.

We believe that combination vaccines are the future of everyday vaccinations for adults,” Bancel added, finding that optimized protection against influenza, Covid-19, and possibly RSV can significantly improve public health outcomes. 

mRNA influenza competition race

 Moderna will face Pfizer and Biontech. This also performs attempts at late stages for  mRNA-based influenza vaccinations. While traditional influenza photos are inactivated with eggs, mRNA vaccines can produce faster, increase flexibility in regular adaptation, and improve efficacy, especially among older adults.  Despite the weaker market for flu vaccinations compared to Covid-19, analysts view combination shots as an important commercial opportunity. Moderna plans to launch a Covid-FLU vaccine combination in 2025 or 2026, subject to successful testing and official approval.

Next Steps The company will present the complete data at upcoming medical conferences and will deliver it to regulators in the US, Europe and other regions in the coming months.

Moderna shares rose after the announcement of pre-market trading when investors welcomed  diversification in their vaccine portfolio amid declining sales of Covid-19-Shot.